Digital assessments designed to support earlier diagnosis, streamline Alzheimer’s trial recruitment, and enable personalised brain health care will be presented by Linus Health at this year’s AAIC in Toronto

Boston-based health tech firm Linus Health will share findings from two oral presentations and eight scientific posters at the Alzheimer’s Association International Conference (AAIC) 2025, taking place now in Toronto and virtually from 27 to 31 July.

The company’s digital cognitive assessment tools, powered by artificial intelligence, are designed to improve early detection of mild cognitive impairment and Alzheimer’s disease, while also offering greater accessibility through remote assessments.

The research being presented explores how digital tools could help detect cognitive decline, personalise care recommendations, and accelerate the recruitment of trial participants by using machine learning to stratify patients more accurately.

“The studies we are presenting at AAIC 2025 represent the next wave of translational science in brain health,” said Linus Health chief executive and co-founder David Bates. “By combining validated digital tools with AI, we are enabling earlier and more accurate detection of mild cognitive impairment, Alzheimer’s disease, and related dementias. At the same time, we are expanding access to proactive brain health support through at-home solutions that empower individuals to engage in their cognitive health journey, helping improve patient outcomes and clinical trial efficiency alike.”

One key area of focus is the potential to streamline trial recruitment through a machine learning model combining Linus Health’s Digital Clock and Recall and Digital Trail Making Test-Part B tools. The platform is being evaluated for its ability to detect both cognitive impairment and amyloid-beta PET status concurrently, helping identify individuals eligible for Alzheimer’s studies while reducing the burden of unnecessary testing.

Other posters explore the use of digital trail-making tests to distinguish cognitive versus motor impairments, the clinical relevance of digital metrics, and how stylus and speech-derived features can be paired with blood-based biomarkers to improve diagnostic accuracy.

Posters also examine the use of semi-supervised clustering to identify subgroups within dementia and MCI populations, as well as the role of language models in personalising brain health support based on individual priorities and preferences.

“For decades, we have recognised that examining the process of how someone performs a cognitive test is just as important as whether they get the answers right,” said David Libon, Linus Health scientific advisor and neuropsychology researcher.

“Our research shows how digital tools can quantify these nuances and bring a more neuropsychologically grounded approach to brain health assessment, and, importantly, one that scales from clinical trials to primary care.”

Linus Health is also previewing enhancements to its life sciences platform at AAIC, including features that enable participants to complete cognitive assessments remotely at home. The company says this aligns with its broader goal to support proactive, accessible brain health at scale.